Author details

Full Name

Judy Kirk

Affiliation

ORCID

Career Start Year

1987

Papers

128

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36785489	Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience.	Aust N Z J Obstet Gynaecol	2023
37864663	Out of the blue: A qualitative study exploring the experiences of women and next of kin receiving unexpected results from BRA-STRAP research gene panel testing.		2023
37270516	Identifying primary and secondary MLH1 epimutation carriers displaying low-level constitutional MLH1 methylation using droplet digital PCR and genome-wide DNA methylation profiling of colorectal cancers.	Clin Epigenetics	2023
37382186	Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial.	Cancer	2023
37253493	Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: the PREDICT study.	BMJ Open	2023
36805919	Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.	Transl Oncol	2023
34906479	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.	Genet Med	2022
36294720	Communicating Personal Melanoma Polygenic Risk Information: Participants' Experiences of Genetic Counseling in a Community-Based Study.	Journal of Personalized Medicine	2022
36013276	What's in a Name? Parents' and Healthcare Professionals' Preferred Terminology for Pathogenic Variants in Childhood Cancer Predisposition Genes.	J Pers Med	2022
36195055	Which Test Is Best? A Cluster-Randomized Controlled Trial of a Risk Calculator and Recommendations on Colorectal Cancer Screening Behaviour in General Practice.	Public Health Genomics	2022
34687117	Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer.	Genes Chromosomes Cancer	2022
34887416	Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing.	NPJ Breast Cancer	2021
34116835	What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12â¿¯months after premenopausal risk-reducing salpingo-oophorectomy.	Gynecol Oncol	2021
33739311	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.	Menopause	2021
33788335	Helping young children understand inherited cancer predisposition syndromes using bibliotherapy.	Journal of Genetic Counseling	2021
34312002	What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12â¿¯months after premenopausal risk-reducing salpingo-oophorectomy.	Gynecol Oncol	2021
33917078	Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development.	Cancers (Basel)	2021
33367756	Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?	Journal of Clinical Endocrinology and Metabolism	2021
33168572	Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility.	J Med Genet	2021
34385669	Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial.	Genet Med	2021
31537406	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.	Eur Urol	2019
30525267	Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.	Breast J	2019
31049413	GP attitudes to and expectations for providing personal genomic risk information to the public: a qualitative study.	BJGP Open	2019
29802966	The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.	Contemp Clin Trials	2018
30157409	Medicare-funded cancer genetic tests: a note of caution.	Med J Aust	2018
29706632	Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma.	Eur J Hum Genet	2018
29301143	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.	Br J Cancer	2018
29599518	Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.	Eur J Hum Genet	2018
29509747	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.	Br J Cancer	2018
29199389	Development and Evaluation of a Telephone Communication Protocol for the Delivery of Personalized Melanoma Genomic Risk to the General Population.	Journal of Genetic Counseling	2018
27957772	Qualitatively understanding patients' and health professionals' experiences of the BRECONDA breast reconstruction decision aid.	Psycho-Oncology	2017
28822557	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling.	Gynecol Oncol	2017
28943990	Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.	Hered Cancer Clin Pract	2017
28452373	Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.	Mod Pathol	2017
28627002	Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?	Br J Dermatol	2017
29031121	Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.	Breast	2017
26574041	New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer.	J Cancer Educ	2017
27702805	A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.	Cancer Epidemiol Biomarkers Prev	2017
27796716	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.	Breast Cancer Res Treat	2017
27684037	Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial.	Genet Med	2017
27677266	Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer.	Fam Cancer	2017
28124295	Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?	Fam Cancer	2017
26534844	Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.	J Med Genet	2016
27329735	When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.	Eur J Hum Genet	2016
26004130	Timing and context: important considerations in the return of genetic results to research participants.	J Community Genet	2016
25391616	Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer.	Fam Cancer	2015
25581431	Identification of six new susceptibility loci for invasive epithelial ovarian cancer.	Nat Genet	2015
24642672	Li-Fraumeni syndrome: cancer risk assessment and clinical management.	Nat Rev Clin Oncol	2014
24240619	Prophylactic gastrectomy in a 16-year-old.	European Journal of Gastroenterology and Hepatology	2014
24323032	Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.	J Clin Oncol	2014